What is the Company actually committing to pay under the proposed plan?

The settlement is valued at approximately $8 billion in present value, or about $10 billion nominal, paid over 25 years. This includes Red River's $1.75 billion increase, of which $1.1 billion goes to the claimant trust, plus a separate $650 million from the Company for plaintiffs' legal fees and expenses. Exact cash timing and accounting treatment will depend on the final plan and court approval.

Why did Red River file for bankruptcy instead of continuing to litigate?

The Company says the Chapter 11 structure is a way to resolve all current and future ovarian claims in one proceeding. It argues that litigation would take decades at the historical pace and that most claimants would never have their day in court. Critics would likely argue that the bankruptcy route limits claimants' options, so the plan's approval by the court will be closely watched.

Does this settlement mean the Company accepts liability for talc-related cancers?

No. The press release states that the Company reiterates that none of the talc-related claims have merit and that the allegations have been rejected by independent experts and regulators. The settlement is presented as a resolution of litigation rather than an admission of liability.

What remains unresolved after this plan?

The Company says the plan would resolve about 99.75% of pending U.S. talc lawsuits. The remaining pending cases relate to mesothelioma, which are being handled outside the plan. The Company says it has already resolved about 95% of mesothelioma lawsuits filed to date. Future claims are intended to be covered by the plan once it is confirmed.

What could prevent or delay this resolution?

The plan must be confirmed by the Bankruptcy Court, and the filing notes significant uncertainty around timing, outcome, and financial impact. Objections from claimants or other parties, appeals, and changes in litigation dynamics could affect the result. The filing's forward-looking statements are subject to the risk factors described in the Company's 10-K and subsequent 10-Q filings.

JNJ 8-K: Regulation FD — Sep 20, 2024

01—Abstract

Summary

Summary of the 8-K filed September 20, 2024. Cited figures are marked; the original filing is the authoritative source.

On September 20, 2024, Johnson & Johnson disclosed that its subsidiary, Red River Talc LLC, filed a voluntary prepackaged Chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas.

The filing seeks to resolve all current and future U.S. ovarian cancer claims arising from cosmetic talc litigation. Red River filed after securing support from approximately 83%^a of current claimants, well above the 75% threshold required under the Bankruptcy Code for plan confirmation. The Future Claims Representative also supports the plan.

To win that support, Red River increased its settlement contribution by $1.75 billion^b, to a present value of approximately $8 billion (about $10 billion nominal, paid over 25 years). Of the increase, Red River committed an additional $1.1 billion to the claimant trust, and the Company separately agreed to contribute $650 million toward plaintiffs' counsel fees and expenses tied to the multi-district litigation. The Company says the plan would resolve 99.75% of pending U.S. talc lawsuits.

Remaining mesothelioma claims are being handled outside the plan, and the Company states it has already resolved about 95%^c of mesothelioma suits filed to date. For investors, the key takeaways are a defined, capped cost for the ovarian talc liability and a path to ending a long-running overhang on the stock.

The Company still disputes the merits of the claims, and the outcome depends on court confirmation, so the timing and final financial impact remain uncertain. The filing is a Regulation FD disclosure and includes forward-looking statements that carry material risk.

02—Key points

Key Highlights

Subsidiary Red River Talc LLC filed a voluntary prepackaged Chapter 11 case to resolve all current and future U.S. ovarian cancer talc claims.
Approximately 83% of current claimants support the plan, exceeding the 75% approval threshold under the U.S. Bankruptcy Code.
Red River increased its settlement contribution by $1.75 billion, bringing the aggregate settlement to a present value of about $8 billion (about $10 billion nominal over 25 years).
The Company agreed to contribute an additional $650 million toward plaintiffs' counsel fees and expenses in the multi-district litigation, on top of Red River's $1.1 billion additional trust funding.
The plan would resolve about 99.75% of pending U.S. talc lawsuits; the remaining mesothelioma cases are being addressed outside the plan.
The Company maintains that none of the talc-related claims have merit and cites a roughly 95% win rate in ovarian cases tried to date.
The Company previously settled State consumer protection claims and talc claims against its former talc suppliers, Imerys and Cyprus, in their bankruptcy cases.

03—Questions

Frequently Asked Questions

What is the Company actually committing to pay under the proposed plan?
The settlement is valued at approximately $8 billion in present value, or about $10 billion nominal, paid over 25 years. This includes Red River's $1.75 billion increase, of which $1.1 billion goes to the claimant trust, plus a separate $650 million from the Company for plaintiffs' legal fees and expenses. Exact cash timing and accounting treatment will depend on the final plan and court approval.
Why did Red River file for bankruptcy instead of continuing to litigate?
The Company says the Chapter 11 structure is a way to resolve all current and future ovarian claims in one proceeding. It argues that litigation would take decades at the historical pace and that most claimants would never have their day in court. Critics would likely argue that the bankruptcy route limits claimants' options, so the plan's approval by the court will be closely watched.
Does this settlement mean the Company accepts liability for talc-related cancers?
No. The press release states that the Company reiterates that none of the talc-related claims have merit and that the allegations have been rejected by independent experts and regulators. The settlement is presented as a resolution of litigation rather than an admission of liability.
What remains unresolved after this plan?
The Company says the plan would resolve about 99.75% of pending U.S. talc lawsuits. The remaining pending cases relate to mesothelioma, which are being handled outside the plan. The Company says it has already resolved about 95% of mesothelioma lawsuits filed to date. Future claims are intended to be covered by the plan once it is confirmed.
What could prevent or delay this resolution?
The plan must be confirmed by the Bankruptcy Court, and the filing notes significant uncertainty around timing, outcome, and financial impact. Objections from claimants or other parties, appeals, and changes in litigation dynamics could affect the result. The filing's forward-looking statements are subject to the risk factors described in the Company's 10-K and subsequent 10-Q filings.

04—Continue

← View all 8-K filings